BioSpace
BioSpace
BioSpace
Iovance wins with Amtagvi and the ADC train chugs on
13 minutes Posted Feb 21, 2024 at 2:00 pm.
0:00
13:30
Download MP3
Show notes

This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.